Academic Journal
A growth modulation index-based geistra score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas : A Spanish group for sarcoma research (GEIS) retrospective study
| العنوان: | A growth modulation index-based geistra score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas : A Spanish group for sarcoma research (GEIS) retrospective study |
|---|---|
| المؤلفون: | MartÃnez-Trufero, Javier, Sande-González, Luis Miguel de, Luna, Pablo, MartÃn-Broto, Javier, Alvarez, Rosa, Marquina, Gloria, Diaz-Beveridge, Roberto, Poveda, Andrés, Cano, Juana MarÃa, Cruz-Jurado, Josefina, López Pousa, Antonio, Salgado, MarÃa Angeles Vaz, Valverde-Morales, Claudia Maria., Sevilla, Isabel, MartÃnez-GarcÃa, Jerónimo, Rubio-Casadevall, Jordi, de Juan Ferre, Ana, Carrasco, Juan Antonio, Moura, David S., Gurruchaga-Sotes, Ibon, Gutiérrez, Antonio |
| سنة النشر: | 2021 |
| المجموعة: | Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB |
| مصطلحات موضوعية: | Trabectedin, Sarcoma, Growth modulation index, Prognostic score, L-sarcoma, GEISTRA |
| الوصف: | Altres ajuts: PharmaMar S.A. ; The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second-or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0-69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1-1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 33672857 |
| Relation: | Cancers; Vol. 13 Núm. 4 (february 2021), p. 1-15; https://ddd.uab.cat/record/272118; urn:10.3390/cancers13040792; urn:oai:ddd.uab.cat:272118; urn:scopus_id:85100802306; urn:pmid:33672857; urn:pmc-uid:7917652; urn:pmcid:PMC7917652; urn:oai:pubmedcentral.nih.gov:7917652 |
| الاتاحة: | https://ddd.uab.cat/record/272118 |
| Rights: | open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ; https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.CE9F1E26 |
| قاعدة البيانات: | BASE |
كن أول من يترك تعليقا!